People with ITP have a type of autoantibody called immunoglobulin G that increases the clearance of platelets from the circulation and can also reduce platelet production. ITP can be very difficult to treat, especially in patients who have not responded well to previous ITP therapies.
The annual rate of newly diagnosed cases of ITP in the U.S. is estimated to be about 3.3 new cases per 100,000 people in the general population. Between adolescence and 60 years of age, ITP is more common in females. The drug, sold under the brand name Vyvgart, has only been approved for treatment of a form of myasthenia gravis, a condition that is caused by autoantibodies and results in broken communications between nerves and muscles.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: